A comparison of @entity618 with XXXX in renal transplant recipients on @entity1140 -based treatment.

@entity1 @entity3442 @entity134 @entity2098 @entity618 @entity1140
We compared the tolerability and efficacy of @entity618 ( @entity2098 ) versus @entity618 (MPS) among renal transplant recipients on @entity1140 -based immunosuppression. The 105 @entity1 who underwent kidney transplantation between January 2002 and March 2008 and were treated with @entity134 , @entity1140 , and a @entity3442 compound were enrolled in the study. From @entity1 files we collected on demographics data, donors, immunosuppressive drug doses, biochemical and hematologic parameters, gastrointestinal and hematologic side effects, and kidney function. Fifty-six @entity1 were prescribed @entity2098 and 49 of them were taking MPS. Demographic parameters and pretransplantation dialysis duration were similar between the 2 groups. After the third month, the MPS dose was higher than that of @entity2098 . There were no clinically important differences between the 2 groups, regarding other immunosuppressive drug doses. Gastrointestinal side effects were similar: 42.4% in the @entity2098 versus 44.8% in the MPS group (P = .846). Six @entity1 in the @entity2098 group and 1 @entity1 in the MPS group underwent a switch of the @entity3442 therapy due to severe gastrointestinal side effects (P = .183). Biopsy-proven acute rejection was reported in 6 @entity1 on @entity2098 and 7 @entity1 on MPS therapy (P = .768). The log-rank test evaluating a 50% reduction in glomerular filtration rate (GFR) showed no significant difference between the 2 groups (P = .719). No deaths were recorded during the study period; there was only 1 graft loss, which occurred in the @entity2098 group. We did not observe a significant difference in tolerability and efficacy between the 2 widely used @entity3442 derivatives. Economic considerations can be an important factor when choosing the drug.
